Bryan E. Stuart

Biography

    Bryan has 20 years of experience building innovative life sciences companies. He was most recently the Chief Business Officer of Civitas Therapeutics. At Civitas, Bryan was responsible for raising capital, business development, commercial and strategy functions, including the IPO and company sale of Civitas to Acorda Therapeutics (NASDAQ: ACOR). Civitas' lead program, CVT-301, was in Phase 3 clinical trials to treat devastating OFF-episodes associated with Parkinson’s disease. Civitas had raised over $100 million in equity capital from leading venture capital and crossover investors including Wellington, RA Capital, Adage, Orbimed, Sofinnova and Partner Funds amongst others.Prior to joining Civitas, Bryan served as Chief of Corporate Development at EKR Therapeutics, a biopharmaceutical business focused on developing and commercializing therapies targeted towards the acute care market, which was sold to Cornerstone Therapeutics (NASDAQ: CRTX) in 2012.Before EKR, Bryan was the Vice President of Corporate and Business Development and M&A for Ovation Pharmaceuticals.  Ovation was a biopharmaceutical company focused on the development and commercialization of therapies targeted towards severe and rare diseases.  The company was built through more than a dozen transactions and strategic partnerships and successfully developed multiple innovative products including Xenazine® for Huntington’s Disease, ONFI® for Lennox-Gaustat Syndrome and Sabril® for infantile spams.  Ovation and was sold to H. Lundbeck A/S in 2009.Bryan began his career as a healthcare investment banker for William Blair & Company.  He holds a Bachelor of Science in Finance with high honors from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the Kellogg School of Management at Northwestern University  

Research Interest